-

Law Offices of Howard G. Smith Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders.

IF YOU ARE A HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER, CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On February 7, 2026, The New York Times reported that the Company would stop selling its version of Wegovy, a popular weight loss drug by competitor Novo Nordisk. A former FDA commissioner was quoted as saying that Hims was “a different technology” than Novo Nordisk’s and that he is “not aware of any clinical trial data that suggests that the product that they wanted to sell actually worked using the technology that they used.”

Contact Us To Participate or Learn More:

If you still hold Hims shares purchased before December 2025 and wish to discuss this matter with us, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Law Offices of Howard G. Smith

NYSE:HIMS

Release Versions

Contacts

Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Deadline Alert: Millrose Properties, Inc. Stockholders Face December 8, 2026 Lead Plaintiff Deadline in Securities Fraud Class Action, The Law Offices of Howard G. Smith Highlights

BENSALEM, Pa.--(BUSINESS WIRE)--Millrose Properties, Inc. ("Millrose" or the "Company") (NYSE: MRP) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by December 8, 2026. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from February 7, 2025 through October 2, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Rubenstsein et al. v....

Deadline Alert: The Chemours Company Stockholders Face December 7, 2026 Lead Plaintiff Deadline in Securities Fraud Class Action, The Law Offices of Howard G. Smith Highlights

BENSALEM, Pa.--(BUSINESS WIRE)--The Chemours Company ("Chemours" or the "Company") (NYSE: CC) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by December 7, 2026. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from February 20, 2026 through August 4, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Darcy v. The Chemours Compan...

Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 21.2% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 2, 2026 disclosure c...
Back to Newsroom